发明名称 Hepatitis C Virus Inhibitors
摘要 The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
申请公布号 US2014205564(A1) 申请公布日期 2014.07.24
申请号 US201414221774 申请日期 2014.03.21
申请人 BRISTOL-MYERS SQUIBB COMPANY 发明人 Romine Jeffrey Lee;St. Laurent Denis R.;Belema Makonen;Snyder Lawrence B.;Hamann Lawrence G.;Kadow John F.;Kapur Jayne;Good Andrew C.;Lopez Omar D.;Lavoie Rico;Bender John A.
分类号 C07D403/14;A61K45/06;A61K38/21;A61K31/7056;A61K31/4725;C07D405/14;A61K31/454;C07D413/14;A61K31/422;A61K31/4184;A61K38/20 主分类号 C07D403/14
代理机构 代理人
主权项 1. A compound of Formula (I)or a pharmaceutically acceptable salt thereof, wherein each m is independently 0 or 1; each n is independently 0 or 1; L is a bond or is selected fromwherein each group is drawn with its left end attached to the benzimidazole and its right end attached to R1; R1 is selected from each R2 is independently selected from alkyl and halo; each R3 is independently selected from hydrogen and —C(O)R7; R4 is alkyl; R5 and R6 are independently selected from hydrogen, alkyl, cyanoalkyl, and halo, or R5 and R6, together with the carbon atoms to which they are attached, form a six- or seven-membered ring optionally containing one heteroatom selected from nitrogen and oxygen and optionally containing an additional double bond; and each R7 is independently selected from alkoxy, alkyl, arylalkoxy, arylalkyl, cycloalkyl, (cycloalkyl)alkyl, heterocyclyl, heterocyclylalkyl, (NRcRd)alkenyl, and (NRcRd)alkyl;provided that when L is other thanand R1 is other thanthen either at least one of R5 and R6 is alkyl or cyanoalkyl, or at least one R7 is arylalkoxy or (cycloalkyl)alkyl.
地址 Princeton NJ US